Eli Lilly and Co
(MIL:1LLY)
€
733.1
-11.4 (-1.53%)
Market Cap: 703.72 Bil
Enterprise Value: 729.10 Bil
PE Ratio: 87.15
PB Ratio: 50.94
GF Score: 66/100 Eli Lilly and Co at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2022 / 03:10PM GMT
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst
Great. Well, thanks, everybody, for joining us. I'm Terence Flynn, the U.S. pharma analyst here at Morgan Stanley. We're very pleased to be hosting Eli Lilly today. Joining us from the company is Anat Ashkenazi, the company's CFO. Thank you so much, Anat, for being here. It's great to see you in person.
Anat Ashkenazi
Eli Lilly and Company - Senior VP & CFO
Absolutely.
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst
Before we get started, for important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.
Questions & Answers
Terence C. Flynn
Morgan Stanley, Research Division - Equity Analyst
Well, again, obviously, a very
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot